Fast ex-Flexus team takes Ar­cus to a quick $100M IPO to ad­vance I/O pipeline

The fast-mov­ing team at Ar­cus has filed for an $100 mil­lion IPO, look­ing to build its im­muno-on­col­o­gy pipeline of small mol­e­cules and an­ti­body com­pounds un­der the lead­er­ship of co-founder Ter­ry Rosen.

Ex­pect­ed to fund the clin­i­cal de­vel­op­ment of lead prod­uct can­di­dates AB928 and AB122 in­to 2020, this round of fundrais­ing fol­lows a $107 mil­lion Se­ries C crossover com­plet­ed just last No­vem­ber. AB928 is a dual adeno­sine re­cep­tor an­tag­o­nist, while AB122 is a PD-1 an­ti­body. Ar­cus had sched­uled a Phase I/II tri­al to test the com­bo in can­cer pa­tients for the first half of this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.